既往接种不同疫苗平台的成人中单价与二价新冠病毒变异株适配RBD蛋白加强疫苗的免疫原性与安全性:一项II/III期随机临床试验
这项随机、安慰剂对照、交叉、双盲II/III期研究评估了ARVACGamma、ARVACOmicron和ARVACBivalent三种重组RBD加强疫苗在既往接种≤3剂新冠加强针成人中的免疫原性、安全性和耐受性。所有疫苗版本较安慰剂显著提高针对新冠病毒变异株的血清转化率;18-60岁人群中所有版本达到主要终点,60岁以上人群中ARVACOmicron和ARVACBivalent达到主要终点。未记录疫苗相关严重不良事件,大多数不良事件为轻度。
要点
- 18-60岁人群中所有ARVAC版本达到主要终点,60岁以上人群中仅ARVACOmicron和ARVACBivalent达到主要终点。
- ARVACBivalent针对多种变异株诱导高血清转化率(>90%),且优于其他ARVAC版本。
- 疫苗诱导的中和抗体提升与既往加强针次数、初免平台及既往新冠感染史无关。
核心结论
- 所有ARVAC疫苗版本较安慰剂显著提高针对新冠病毒变异株的血清转化率。
- 18-60岁人群中所有版本达到主要终点,60岁以上人群中ARVACOmicron和ARVACBivalent达到主要终点。
- ARVACBivalent针对多种变异株诱导高血清转化率(>90%)且优于其他ARVAC版本。
研究设计与样本
- 随机、安慰剂对照、交叉、双盲II/III期研究,评估ARVACGamma、ARVACOmicron和ARVACBivalent三种重组RBD加强疫苗。
- 研究对象为既往接种≤3剂新冠加强针的成人,主要终点为中和抗体血清转化率较安慰剂及对疫苗抗原同源变异株>75%血清转化率。
主要发现
- 所有疫苗版本较安慰剂显著提高针对新冠病毒变异株的血清转化率。
- 18-60岁人群中所有版本达到主要终点;60岁以上人群中ARVACOmicron和ARVACBivalent达到主要终点。
- 未记录疫苗相关严重不良事件,大多数不良事件为轻度。
- 接种任何疫苗者血浆抗棘突特异性IgG和唾液抗S1特异性IgA水平均升高。
- 疫苗诱导的血浆中和抗体提升与既往加强针次数(0、1或2剂)、初免疫苗平台(腺病毒、单剂腺病毒、mRNA、灭活病毒、异源接种和病毒样颗粒[VLP])及既往新冠感染史无关。
关键数值与推荐
- 主要终点为中和抗体血清转化率较安慰剂及对疫苗抗原同源变异株>75%血清转化率。
- 18-60岁人群中所有ARVAC版本达到主要终点;60岁以上人群中ARVACOmicron和ARVACBivalent达到主要终点。
- ARVACBivalent针对多种变异株血清转化率>90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A randomized, placebo-controlled, crossover, double-blind, phase II/III study was conducted to evaluate the immunogenicity, safety, and tolerability of a recombinant booster vaccine (ARVAC) containing the SARS-CoV-2 spike protein receptor binding domain in three versions: ARVACGamma, ARVACOmicron, and ARVACBivalent in adults with ≤3 previous SARS-CoV-2 booster doses. Primary endpoint was seroconversion rate of neutralizing antibodies compared to placebo and to a > 75 % seroconversion rate to vaccine antigen homologous variants. All vaccine versions significantly increased seroconversion rates to SARS-CoV-2 variants compared to placebo. In participants aged 18-60 years, all versions met the primary endpoint; in those over 60 years old, ARVACOmicron and ARVACBivalent met this endpoint. No vaccine-related serious adverse events were recorded, and most adverse events were mild. Plasma levels of anti-spike-specific IgG and anti-S1-specific IgA in saliva increased in participants receiving any vaccine. The increase in plasma neutralizing antibodies induced by the vaccine was independent of the number of previous booster doses (0, 1 or 2), the primary vaccine platform (adenovirus, single-dose adenovirus, mRNA, inactivated virus, heterologous vaccination, and virus-like particle [VLP]) and the history of previous COVID-19. The neutralizing Ab response induced by the vaccine in healthy participants was similar to that triggered in participants with underlying medical conditions associated with an increased risk of severe COVID-19. ARVACBivalent induced high seroconversion rates (>90 %) against multiple variants and was superior to other ARVAC-versions. It increased neutralizing antibodies against SARS-CoV-2 variants (Ancestral, Gamma, Omicron, XBB and JN.1) and SARS-CoV-1. (NCT05752201).
引用
- Perez Marc G, Coria LM, Ceballos A, et al. Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial. Vaccine. 2025. PMID: 40179522. doi:10.1016/j.vaccine.2025.127045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。